]) (P Ն .05). (Figure 1 and Figure 2 ), but only 2 SCCs showed amplification for RAR␤1Ј. The findings for RAR␤, RAR␤1, and RAR␤2,4 were indistinct.
Comment.
Based on the different retinoid sensitivity of BCC and SCC, we expected RAR isoform differences. Interestingly, only 2 of 22 SCCs expressed RAR␤1Ј at a much lower level than BCCs (9%). In contrast to lung cancer, RAR␤1Ј does not seem to be pivotal for retinoid chemoprevention in SCC. Levels of RAR␣ and RAR␥ were higher in BCC than in SCC, which fits with reported RAR and retinoid X receptor (RXR) isoform expression.
2
Other factors may mediate chemoprevention. Acitretin binds with low affinity to RARs but with high affinity to cellular retinoic acid binding proteins (CRABPs). Acitretin shifts the distribution of endogenous tretinoin from CRABPs to RAR-RXR heterocomplexes, potentiating its effect. Tazarotene specifically activates RAR␤ and RAR␥ and only weakly activates RAR␣ with chemopreventive effect on BCC in Ptch1± mice.
3 In human lung cancer, RAR␤4 seems carcinogenic. 4 Differential activation of RAR isotypes may therefore have carcinogenic or anticarcinogenic effects as shown by the relative superiority of tazarotene in BCC over other retinoid-related compounds with simultaneous RAR␣ and RAR␤ isoform activation. In summary, RAR isoform mRNA expression differs between BCC and SCC. Unlike in lung cancer, the mRNA levels of the recently reported isoform RAR␤1Ј do not explain SCC retinoid sensitivity. Rather, we assume, the relative sensitivity to retinoid treatment of SCC vs BCC is mediated by differential RAR activation or indirect effects such as shifting endogenous retinoids from CRABPs to RAR-RXR heterocomplexes.
